Evidence map›Paper›PMID 40708980›Full record

ArticleBioengineering & translational medicine2025

Bisulfite-free

Zhicong Yang, Qing Chen, Shihua Dong, Peng Xu, Zhanrui Mao, Yaping Dong, Wei Li, Wenxuan Li, Yang Han, Lihe Dai and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering & translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Bisulfite-freeBioengineering & translational medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zhicong YangShanghai Public Health Clinical Center, Huashan Hospital, Cancer Metastasis Institute, Institutes of Biomedical Sciences Fudan University Shanghai China.
Qing ChenDepartment of Urology, Changhai Hospital Naval Medical University Shanghai China.
Shihua DongShanghai Public Health Clinical Center, Huashan Hospital, Cancer Metastasis Institute, Institutes of Biomedical Sciences Fudan University Shanghai China.
Peng XuShanghai Public Health Clinical Center, Huashan Hospital, Cancer Metastasis Institute, Institutes of Biomedical Sciences Fudan University Shanghai China.
Zhanrui MaoShanghai Public Health Clinical Center, Huashan Hospital, Cancer Metastasis Institute, Institutes of Biomedical Sciences Fudan University Shanghai China.
Yaping DongDepartment of Urology, Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
Wei LiDepartment of radiotherapy Fudan University Shanghai Cancer Center Shanghai China.
Wenxuan LiShanghai Public Health Clinical Center, Huashan Hospital, Cancer Metastasis Institute, Institutes of Biomedical Sciences Fudan University Shanghai China.
Yang HanCAS Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, School of Future Technology, Beijing Institute of Genomics University of Chinese Academy of Sciences Beijing China.
Lihe DaiDepartment of Urology, Changhai Hospital Naval Medical University Shanghai China.
Gehong DongBeijing Tiantan Hospital Capital Medical University Beijing China.
Yong ZhangBeijing Tiantan Hospital Capital Medical University Beijing China.
Yinshan LiPeople's Hospital of Ningxia Hui Autonomous Region Ningxia Medical University Ningxia China.
Liang ChengDepartment of Pathology and Laboratory Medicine, Department of Surgery (Urology) BrownUniversity Warren Alpert Medical School and the Legorreta Cancer Center, Brown University Providence Rhode Island USA.
Weimin CiCAS Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, School of Future Technology, Beijing Institute of Genomics University of Chinese Academy of Sciences Beijing China.
Wenqiang YuShanghai Public Health Clinical Center, Huashan Hospital, Cancer Metastasis Institute, Institutes of Biomedical Sciences Fudan University Shanghai China.
Chuanliang XuDepartment of Urology, Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.ORCID https://orcid.org/0000-0003-2622-8348

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urothelial carcinomas (UCs) are the fourth most common male malignancies. However, currently implemented detection methods for UC are usually invasive and/or show passable sensitivity and specificity. An accurate, practical, and effective approach is urgently needed for UC clinical detection. Based on the observation that

Indexed as

early noninvasive detectionPCDHGB7 evaluationurothelial carcinoma

Identifiers

PMID40708980
PMCPMC12284432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.